Seroprevalence of COVID-19 in Blood Donors: A Systematic Review and Meta-Analysis

Table 2

Seroprevalence of COVID-19 in blood donors in the studied subgroups.

Subgroups		Number of study	Prevalence (95% CI)	I^2 (%)	value
Total		28	10% (9%–11%)	99.6	<0.001
Sex	Male	12	5% (4%–7%)	99.3	<0.001
	Female	12	6% (4%–7%)	99.3	<0.001
Country	Canada	2	4% (1%–8%)	99.8	<0.001
	Germany	1	1% (1%–1%)	0	—
	Denmark	3	9% (4%–15%)	99.4	<0.001
	Saudi Arabia	3	10% (2%–17%)	99.4	<0.001
	USA	3	6% (4%–9%)	99.5	<0.001
	South Africa	1	2% (2%–3%)	0	—
	Italy	3	10% (3%–16%)	99.2	<0.001
	France	1	3% (2%–4%)	0	—
	Netherlands	1	3% (2%–3%)	0	—
	Brazil	2	5% (3%–6%)	92.1	<0.001
	Kenya	1	9% (9%–10%)	0	—
	India	4	32% (12%–52%)	99.6	<0.001
	Mexico	1	69% (65%–73%)	0	—
Continent	North America	7	10% (8%–12%)	99.7	<0.001
	Europe	9	7% (4%–9%)	99.4	<0.001
	Asia	7	23% (14%–31%)	99.6	<0.001
	Africa	2	4% (1%–7%)	98.8	<0.001
	South America	2	5% (3%–6%)	92.1	<0.001
Blood group	A	13	12% (10%–14%)	99.5	<0.001
	B	13	12% (10%–15%)	99.5	<0.001
	AB	13	9% (7%–12%)	99.6	<0.001
	O	13	13% (11%–16%)	99.6	<0.001
Antibody isotypes reported	IgG	9	23% (18%–29%)	99.8	<0.001
	IgM	5	29% (9%–49%)	99.8	<0.001